Here is a summary of health news briefs.
Developing world should reap benefits of new monkeypox research, experts urge
As cases of monkeypox in wealthier Western countries spark a wave of scientific research to tackle the epidemic, scientists are urging the world to ensure that low-income countries also benefit from the fruits of this labor. According to the World Health Organization (WHO), more than 550 confirmed cases of monkeypox have been reported from at least 30 countries outside of Africa, where the virus is commonly present.
Vaccination during pregnancy reduces childhood infections; vaccines only modestly reduce long-term COVID risk
Here is a summary of some recent studies on COVID-19. They include research that deserves further study to corroborate the findings and that has not yet been certified by peer review. Vaccines in pregnancy reduce infants’ risk of COVID-19
Pfizer’s Paxlovid reduces risk of COVID in older adults, regardless of vaccination status – study
Pfizer Inc’s antiviral treatment Paxlovid reduces COVID-19-related hospitalization and death rates in vaccinated and unvaccinated patients 65 years and older, according to a new study in Israel conducted during the rise of the Omicron variant of the coronavirus. However, the treatment failed to prevent serious illness in young adults, according to a study by Clalit Health Services, Israel’s largest healthcare provider.
J&J, cancer drug AbbVie significantly slows progression of rare lymphoma: study
Johnson & Johnson and AbbVie’s best-selling leukemia drug Imbruvica, in combination with standard treatment, has controlled a rare type of non-Hodgkin’s lymphoma for more than two years longer than standard treatment alone in elderly patients , according to data presented on Friday. Patients aged 65 and over with mantle cell lymphoma (MCL) received Imbruvica or placebo along with a chemotherapy regimen of bendamustine and the autoimmune drug rituximab.
Immunizations for young children could start ‘in earnest’ by June 21 – White House
The White House expects vaccinations for young children to begin in earnest as soon as June 21, if federal authorities approve their use in the coming weeks, White House COVID Response Coordinator Ashish Jha said Thursday. . Jha told reporters that the US government has enough COVID-19 vaccines from Pfizer Inc and Moderna Inc to begin the program for young children if and when the vaccines are approved.
Factbox-Latest on the global spread of the coronavirus
South Korea’s prime minister said on Friday the country would lift its quarantine requirement for foreign arrivals without vaccinations from June 8 and would also start lifting aviation regulations imposed on international flights. DEATHS AND INFECTIONS
Test makers target monkeypox market as cases rise
Diagnostics companies are racing to develop tests for monkeypox, hoping to tap into a new market as governments step up efforts to trace the world’s first major outbreak of viral infection outside of Africa. The rush began last month, much like early 2020 when companies rushed to manufacture kits to help diagnose COVID-19, creating a multi-billion dollar windfall for test makers.
Bristol Myers bolsters cancer drug portfolio with $4.1 billion Turning Point deal
Bristol Myers Squibb announced on Friday that it will acquire drug developer Turning Point Therapeutics Inc for $4.1 billion in cash to gain access to promising targeted cancer treatments. Turning Point’s lead drug, repotrectinib, targets mutations in certain proteins in the body that lead to uncontrolled cell growth, a hallmark of cancer.
Federal investigators to review FDA response to infant formula recall
Federal investigators have launched a review to determine whether the U.S. Food and Drug Administration properly inspected Abbott Laboratories’ Michigan plant and how the agency oversaw the infant formula recall that led to severe shortages in the USA. The review, which is expected to be completed in 2023, will be conducted by the Office of Inspector General (OIG) of the U.S. Department of Health and Human Services, according to a notice posted Thursday on its website.
US FDA staff say Novavax vaccine reduces risk of COVID
US Food and Drug Administration staff said on Friday that Novavax Inc’s vaccine reduces the risk of mild to severe COVID-19 and that it is likely the vaccine may provide some level of protection against the variant. Omicron. The FDA analyzed data from the Novavax trial before the Omicron and Delta variants became the dominant strains.
(With agency contributions.)